CJC-1295 without DAC 5mg + IPA 5mg

Compound Overview

This lyophilized blend brings together two complementary GH-axis research peptides. CJC-1295 No DAC stimulates the GHRH receptor on pituitary somatotrophs, while Ipamorelin activates the ghrelin receptor (GHSR-1a). Because the two compounds engage separate pituitary signaling pathways, this pairing is used in laboratory models evaluating whether dual-receptor stimulation may produce synergistic GH release.

Research Background & Published Literature

The CJC-1295/Ipamorelin combination is frequently examined in preclinical GH-axis research because it combines GHRH receptor stimulation with ghrelin receptor activity. Published literature explores how concurrent signaling through these pathways may amplify GH output compared with either peptide studied independently.

Researchers reviewing the literature around this compound can use the peer-reviewed resources below for additional context on mechanism of action, signaling pathways, and controlled laboratory research applications:

• Teichman et al. (2006) — J Clin Endocrinol Metab
• Raun et al. (1998) — Eur J Endocrinol

Storage, Handling & Stability Guidelines

Store the lyophilized blend at -20°C for long-term stability. After reconstitution, keep research material at 2–8°C and use within 14 days.

• Keep exposure to ambient temperature brief during handling to help preserve compound integrity.
• Reseal vials promptly after each withdrawal to limit moisture exposure.
• Use appropriate personal protective equipment and follow institutional chemical safety protocols at all times.
• For traceability, label all aliquots with compound name, concentration, reconstitution date, and operator initials.

Lab Verification

Nexus maintains batch-level verification records for research compounds in the Lab Verified archive, including HPLC purity review and Mass Spectrometry identity confirmation where current lot data is available.